{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:00:34Z","timestamp":1790341234350,"version":"4.1.0"},"reference-count":14,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,6]]},"abstract":"Abstract<\/jats:title>\n \n Context<\/jats:title>\n Since 2020, a smartphone app (Melon NikkiTM) that is used in conjunction with the electronic drug delivery device (GROWJECTORTM L) has been available in Japan. Real-world data generated through this system enable evaluation of treatment adherence among pediatric patients receiving GH therapy.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To assess adherence to home-based GH self-injection using a smartphone application linked to an electronic injection device and identify factors associated with adherence.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n Observational study<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n Real-world data were collected and analyzed, including home injection patterns, GH dosage, and changes in height and body mass index over the first year of therapy. Factors significantly associated with adherence outcomes were evaluated using statistical analyses.<\/jats:p>\n <\/jats:sec>\n \n Patients<\/jats:title>\n We enrolled a cohort of Japanese pediatric patients with various indications for GH therapy who used an electronic injection device connected to the Melon NikkiTM application.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Injection adherence declined after the second month in patients with GH deficiency and after the fourth month in patients born small for gestational age, particularly among those with variable injection times. Multivariate analysis showed that cumulative app usage up to 24 weeks is an independent factor that significantly contributes to an increase in the cumulative injection rate. Use of the application was associated with better adherence during initial 8 weeks.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Use of a smartphone application linked to an electronic injection device may support adherence maintenance during the early phase of GH therapy. These findings provide clinically relevant insights that may inform patient guidance and adherence-focused interventions.<\/jats:p>\n <\/jats:sec>","DOI":"10.1210\/jendso\/bvag113","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:01:42Z","timestamp":1778760102000},"source":"Crossref","is-referenced-by-count":0,"title":["Adherence to daily growth hormone therapy in Japan: real-world data from the Melon NikkiTM app and device"],"prefix":"10.1210","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7417-8923","authenticated-orcid":false,"given":"Akari","family":"Nakamura-Utsunomiya","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Hiroshima North Medical Center, Asa Citizens Hospital , Hiroshima 731-0293 ,","place":["Japan"]},{"name":"Department of Medical Genetics, Biomedical and Health Sciences, Hiroshima University Graduate School , Hiroshima 734-8551 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hiroshima University Hospital , Hiroshima 734-8551 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Arashin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hiroshima North Medical Center, Asa Citizens Hospital , Hiroshima 731-0293 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"issue":"1","key":"2026092508113706000_bvag113-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1297\/cpe.2021-0044","article-title":"History of GH treatment in Japan","volume":"31","author":"Tanaka","year":"2022","journal-title":"Clin Pediatr Endocrinol"},{"issue":"8","key":"2026092508113706000_bvag113-B2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1210\/jcem-18-8-901","article-title":"Treatment of a pituitary dwarf with human growth hormone","volume":"18","author":"Raben","year":"1958","journal-title":"J Clin Endocrinol Metab"},{"issue":"5732","key":"2026092508113706000_bvag113-B3","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/281544a0","article-title":"Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone","volume":"281","author":"Goeddel","year":"1979","journal-title":"Nature"},{"key":"2026092508113706000_bvag113-B4","doi-asserted-by":"crossref","first-page":"980979","DOI":"10.3389\/fendo.2022.980979","article-title":"What do we do now that the long-acting growth hormone is here?","volume":"13","author":"Miller","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"2026092508113706000_bvag113-B5","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1210\/clinem\/dgad183","article-title":"Weekly somapacitan in GH deficiency: 4-year efficacy, safety, and treatment\/disease burden results from REAL 3","volume":"108","author":"S\u00e4vendahl","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026092508113706000_bvag113-B6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000493211","article-title":"Identifying potentially modifiable factors associated with treatment non-adherence in paediatric growth hormone deficiency: a systematic review","volume":"90","author":"Graham","year":"2018","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"2026092508113706000_bvag113-B7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1515\/jpem-2017-0157","article-title":"Adherence to growth hormone therapy in children and its potential barriers","volume":"31","author":"Mohseni","year":"2018","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2","key":"2026092508113706000_bvag113-B8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1297\/cpe.30.85","article-title":"Effectiveness of a smartphone application on medication adherence in children with short stature receiving GH therapy: a multicenter prospective cohort study (GTL-app)","volume":"30","author":"Urakami","year":"2021","journal-title":"Clin Pediatr Endocrinol"},{"issue":"3","key":"2026092508113706000_bvag113-B9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/archpedi.156.3.230","article-title":"Effect of growth hormone therapy on height in children with idiopathic short stature: a meta-analysis","volume":"156","author":"Finkelstein","year":"2002","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"Suppl 3","key":"2026092508113706000_bvag113-B10","first-page":"128","article-title":"Growth hormone treatment in short Japanese children born small for gestational age","volume":"62","author":"Horikawa","year":"2004","journal-title":"Horm Res"},{"issue":"Suppl 3","key":"2026092508113706000_bvag113-B11","first-page":"350","article-title":"Growth and growth hormone treatment in short stature children born small for gestational age","volume":"6","author":"Labarta","year":"2009","journal-title":"Pediatr Endocrinol Rev"},{"issue":"4","key":"2026092508113706000_bvag113-B12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/jama.2016.19975","article-title":"Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial","volume":"317","author":"Beck","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"2026092508113706000_bvag113-B13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","article-title":"Continuous glucose monitoring and metrics for clinical trials: an international consensus statement","volume":"11","author":"Battelino","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2026092508113706000_bvag113-B14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/jpepsy\/jsaa007","article-title":"Does self-efficacy mediate the link between impulse control and diabetes adherence?","volume":"45","author":"Silva","year":"2020","journal-title":"J Pediatr Psychol"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvag113\/68295061\/bvag113.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/6\/bvag113\/68295061\/bvag113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/6\/bvag113\/68295061\/bvag113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:11:45Z","timestamp":1790338305000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvag113\/8679136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,6]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvag113","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,6]]},"article-number":"bvag113"}}